PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate an

PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submiss

Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company report

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse

Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse

PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse

PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consen

Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Mole

PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study

PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer

PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight t

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst con

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst con

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst con

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst conse

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m

Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) t

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m

Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst conse

Jefferies analyst Kambiz Yazdi initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating a

Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586)

HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and m

Fiscal Year 2023 Financial ResultsAs of December 31, 2023, PMV Pharma had $228.6 million in cash, ca

Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as o

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on PMV Pharma (NASDAQ:PMVP) with a B

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst conse

HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lo

Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the comp

PMV Pharmaceuticals Inc (NASDAQ: PMVP) announced updated Phase 1 results from its ongoing Phase 1/2

Updated PC14586 Phase 1 data presented today as a late-breaking poster at 2023 AACR-NCI-EORTC Intern

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and d

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enh

 Late-breaking poster presentation to highlight updated Phase 1 clinical data of PC14586, a first-in

HC Wainwright & Co. analyst Robert Burns maintains PMV Pharma (NASDAQ:PMVP) with a Buy and lo